NEW YORK, Oct. 28 /PRNewswire/ -- See video from AstraZeneca at:
Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the third quarter declined by 2% at constant exchange rates (CER) to $7,898 million. Strong double-digit sales growth at CER for Crestor, Symbicort and Seroquel XR. Revenue in markets outside the US increased by 7% at CER, including a 14% increase in Emerging Markets.
As expected, revenue in the US was affected by generic competition for Arimidex, Pulmicort Respules and Toprol-XL, as well as the absence of H1N1 pandemic influenza vaccine revenue that benefited the third quarter 2009. US revenue was down 13% in the third quarter. Available video includes headquarters, laboratory and production shots
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE and ZDF.
Registered journalists can access video, audio, text, graphics and photos at http://www.thenewsmarket.com.
If you are not already registered, please take a moment to sign up - registration is quick and free: http://www.thenewsmarket.com/registration
Story Id: 20226
SOURCE thenewsmarket.com; AstraZeneca